Previous 10 | Next 10 |
2024-01-02 02:37:43 ET More on Galapagos: Galapagos: Navigating Uncharted CAR-T Waters With A Cash Compass Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca business to Alfasigma For further details see: Galapagos to transfe...
Transaction expected to close in the first quarter of 2024, subject to customary closing conditions Michele Manto, Galapagos’ Chief Commercial Officer, to join Alfasigma Mechelen, Belgium; 02 January 2024, 07:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and Alfa...
Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 study to evaluate the safety, efficacy, and feasibility of our seven-day vein-to-vein, point-of-care manufactured BCMA CAR-T...
2023-12-13 11:51:32 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Galapagos (NASDAQ: GLPG ) just reported results for the third quarter of 2023. Galapagos reported earnings per share of 42 cents. This was above the analyst estimate for E...
2023-12-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancers Two poster presentations include recent data updates and additional data not included in the A...
Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition in San Diego, CA, on Sunday, December 10, 2023, from 11:00 am PST to 12:30 pm PST. The i...
2023-11-21 11:00:00 ET Summary Galapagos pivots to CAR-T therapy, divesting Jyseleca; faces clinical, market risks amidst investor skepticism. Revenue up 9% YOY; operating losses reduced; strong cash reserve at $4.2B; net profit achieved. Negative enterprise value and underper...
2023-11-05 09:14:09 ET Galapagos NV (GLPG) Q3 2023 Earnings Conference Call November 3, 2023 08:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO & COO Jeevan Shetty - Head of ...
2023-11-02 16:59:53 ET More on Galapagos Galapagos: Good To Have An Approval, Bad To Have No Major Catalysts Galapagos Q3 2023 Earnings Preview Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca business to Alfasigma Seek...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...